Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma

Akira Watanabe,1 Hideki Suzuki,1 Takehiko Yokobori,1 Mariko Tsukagoshi,1 Bolag Altan,1 Norio Kubo,1 Shigemasa Suzuki,1 Kenichiro Araki,1 Satoshi Wada,1 Kenji Kashiwabara,2 Yasuo Hosouchi3 and Hiroyuki Kuwano1

1Department of General Surgical Science, Gunma University Graduate School of Medicine, Gunma; 2Pathological Department, Gunma Prefecture Saiseikai-Maebashi Hospital, Gunma; 3Department of Surgery and Laparoscopic Surgery, Gunma Prefecture Saiseikai-Maebashi Hospital, Gunma, Japan

Key words
Cancer progression, drug resistance, extrahepatic cholangiocarcinoma, p27, stathmin1

Correspondence
Akira Watanabe, Department of General Surgical Science (Surgery I), Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan.
Tel: +81 2 7220 8224; Fax: +81 2 7220 8230; E-mail: akira.watanabe@gunma-u.ac.jp

Funding information
None declared.

Received February 9, 2014; Revised April 3, 2014; Accepted April 6, 2014
Cancer Sci 105 (2014) 690–696
doi: 10.1111/cas.12417

Cholangiocarcinoma is associated with poor prognosis and its incidence and mortality are increasing worldwide.1 The 5-year survival rate for cholangiocarcinoma is 10–40%.2 Cholangiocarcinoma is defined as intrahepatic or extrahepatic (EHCC), the latter of which consists of hilar or bile duct tumors. Surgical therapy is the only effective curative treatment for EHCC; postoperative survival is dependent on the existence of invasion and metastasis.3,4 Therefore, to improve patient prognoses, we must understand the mechanism of cancer progression in EHCC.

Stathmin1 (STMN1) is a major cytosolic phosphoprotein that regulates microtubule dynamics by preventing tubulin polymerization and promoting microtubule destabilization. STMN1 plays an important role in a variety of biological processes, including carcinogenesis. STMN1 is highly expressed in various types of human malignancies and is therefore also known as oncprotein 18 (OP18). Moreover, STMN1 expression correlates with tumor progression and poor prognosis in the following cancers: breast cancer,5–7 prostate cancer,8 gastric cancer,9,10 hepatocellular carcinoma,11,12 oral squamous cell carcinoma,13 colorectal cancer,14,15 malignant mesothelioma16 and urothelial carcinoma.17 Thus, STMN1 is a fundamental cancer-associated gene and a potential target for diagnosis and treatment. To our knowledge, STMN1 expression in EHCC has not been reported; therefore, we explored the role of STMN1 in EHCC.

STMN1 regulates microtubule metabolism and contributes to tumor progression. Baldassarre et al.18 reported that STMN1 bound to p27 suppressed the function of p27 and enhanced the proliferation of tumor cells. p27 was discovered as an inhibitor of cyclin-dependent kinase (CDK) complexes in TGF (transforming growth factor) b-arrested cells and was classified as a member of the Cip/Kip family of cyclin-dependent kinase inhibitors (CKI).19 The CKI associate with a broad spectrum of cyclin–CDK complexes to negatively regulate progression through the G1 phase of the cell cycle. More recently, cytoplasmic p27 was shown to play a role in the regulation of cell migration.20 However, there are still few reports that discuss the relationship of STMN1 and p27 in malignancy, including EHCC. Therefore, we examined the relationship between STMN1 and p27 in EHCC.

The purpose of the present study was to clarify the function of STMN1 in EHCC cell lines in vitro, determine the clinical significance of STMN1 in primary EHCC and evaluate the relationship between STMN1 and p27. To this end, we performed immunohistochemistry to evaluate the relationships between STMN1, p27 and clinicopathological factors in clinical EHCC samples. We also examined the in vitro effects of
siRNA-mediated STMN1 suppression on the proliferation, chemo- therapeutic sensitivity and p27 expression in human EHCC cell lines.

Material and Methods

Patients and samples. Immunohistochemistry was performed on 80 EHCC patients who had undergone curative surgery in our department between 1995 and 2011. Patients ranged in age from 43 to 94 years. Tumor stage was classified according to the seventh tumor–node–metastasis (TNM) classification of the Union for International Cancer Control (UICC).42 Forty-four (55%) patients received adjuvant therapy following chemotherapy: 11 received UFT (tegafur-uracil; Taiho Pharmaceutical, Tokyo, Japan); nine received Gemcitabine (Eli Lilly and Company, Indianapolis, IN, USA); 21 received S-1 (TS-1; Taiho Pharmaceutical); and three received Gemcitabine+S-1. All patients provided written informed consent, as per institutional guidelines.

Immunohistochemical staining. A 4-μm section was cut from paraffin blocks of EHCC samples. Each section was mounted on a silane-coated glass slide, deparaffinized and soaked for 30 min at room temperature in 0.3% H2O2/methanol to block endogenous peroxidases. The sections were then heated in boiled water and Immunosaver (Nishin EM, Tokyo, Japan) at 98°C for 30 min. Endogenous non-specific binding sites were blocked by incubating with Protein Block Serum-Free (DAKO, Carpinteria, CA, USA) for 30 min. A mouse monoclonal anti-STMN1 (OP18) antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a mouse monoclonal anti-p27 antibody (Santa Cruz Biotechnology) were applied at a dilution of 1:100 for 24 h at 4°C. The primary antibody was visualized using the Histofine Simple Stain PO (M) Kit (Nichirei, Tokyo, Japan) according to the instruction manual. The chromogen 3,3′-diaminobenzidine tetrahydrochloride was applied as a 0.02% solution containing 0.005% H2O2 in 50 mM ammonium acetate-citrate acid buffer (pH 6.0). The sections were lightly counterstained with Mayer’s hematoxylin and mounted. Negative controls were established by omitting the primary antibody and no detectable staining was evident. We previously confirmed that esophageal carcinomas express STMN1 and p27; therefore, esophageal carcinomas were used as a positive control (Figs S1–S3).

Immunohistochemical staining results were evaluated as described by Altan et al.22 The intensity of cytoplasmic STMN1, nuclear p27 and cytoplasmic p27 staining was scored as follows: 0, no staining; 1+, weak staining; 2+, moderate staining; and 3+, strong staining relative to the positive control (Figs S1–S3). The percentage of nuclear-stained cells was calculated by examining at least 1000 cancer cells in five representative areas. Cytoplasmic STMN1, nuclear p27 and cytoplasmic p27 were scored as follows: 0, no staining; 1+, 1–10%; 2+, 11–50%; and 3+, 51–100%. The score was defined as the percentage score multiplied by the intensity score according to the criteria presented in Table S1 (0, 1+, 2+, 3+, 4+, 6+ and 9+). The optimal cut-off point was defined as follows: grades 0, 1, 2, 3 and 4 were considered low expression, while grades 6 and 9 were designated as high expression. All samples were evaluated by two observers (AW, TY). The Ki-67 labeling index was used to calculate the percentage of cells with high nuclear expression cells in approximately 1000 cells per sample.23

Cell culture. The human EHCC cell line HuCCT-1 was used in the present study. All cells were obtained from RIKEN BRC through the National Bio-Resource Project of MEXT, Tokyo, Japan. The cells were cultured in RPMI 1640 medium (Wako, Osaka, Japan) supplemented with 10% FBS and 1% penicillin–streptomycin (Invitrogen, Carlsbad, CA, USA).

siRNA transfection. STMN1-specific siRNA (Silencer Pre-designed siRNA) was purchased from Bonac Corporation (Fukuoka, Japan). HuCCT-1 cells were seeded in six-well, flat-bottom microtiter plates at a density of 1 × 104 cells per well in a volume of 2 mL and incubated in a humidified atmosphere (37°C and 5% CO2). After incubation, 500 μL of Opti-MEM I Reduced Serum Medium (Invitrogen), 5 μL Lipofectamine RNAi MAX (Invitrogen) and 5 μL STMN1-specific siRNA (50 nM final concentration in each well) were mixed and incubated for 20 min to form chelate bonds. The siRNA reagents were then added to the cells. The experiments were performed after 24–96 h of incubation.

Proximity ligation assay (PLA). HuCCT1 cells were seeded and incubated on Chamber Slides (Lab-Tek II, Thermo Scientific, Waltham, MA, USA) for 24 h. The cells were fixed with 4% paraformaldehyde for 30 min and 100% methanol for 10 min. The slides were then blocked with 4% bovine serum albumin (Millipore, Billerica, MA, USA) for 30 min and incubated for 48 h at 4°C with the appropriate combinations of mouse, rabbit and goat antibodies diluted 1:100 (STMN1 rabbit antibody; Cell Signaling Technology, Danvers, MA, USA; and p27 mouse antibody; Santa Cruz Biotechnology) in antibody dilution solution (Olink Biosciences, Uppsala, Sweden). The slides were incubated with Duolink PLA Rabbit MINUS and PLA Mouse PLUS proximity probes (Olink Bioscience) and a proximity ligation was performed using the Duolink Detection Reagent Kit (Olink Bioscience) according to the manufacturer’s protocol. Nuclei were stained with Duolink In Situ Mounting Medium with DAPI (Olink Bioscience). Images were acquired with an All-in-one Fluorescence Microscope (Keyence Corporation, Osaka, Japan).

Protein extraction and western blot analysis. Transfected cells were incubated for 96 h. Total protein was extracted using the PRO-PREP Protein Extraction Solution Kit (iNTRON Biotechnology, Sungnam, Kyungki-Do, Korea) and nuclear protein was extracted with the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific, Kanagawa, Japan). The membranes were incubated overnight at 4°C with mouse monoclonal antibodies against STMN1 (1:1000; Santa Cruz Biotechnology), p27 (1:1000; Santa Cruz Biotechnology), β-actin (1:1000; Sigma, St Louis, MO, USA) and Histone H1 (1:1000; Santa Cruz Biotechnology). The membranes were then treated with horseradish peroxidase-conjugated anti-mouse secondary antibodies and the proteins were detected with the ECL Prime Western Blotting Detection System (GE Healthcare, Tokyo, Japan).

Proliferation assay. Cell proliferation was measured with the Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan). At 48 h after transfection, the HuCCT1 cells were plated (approximately 5000 cells per well) in 96-well plates in 100 μL of medium containing 10% FBS. Evaluations were performed at the following time points: 0, 24, 48, 72 and 96 h. To determine cell viability, 10 μL of cell counting solution was added to each well and incubated at 37°C for 2 h. Next, the absorbance of each well was detected at 450 nm using a xMark Microplate Absorbance Spectrophotometer (Bio Rad, Hercules, CA, USA).

Paclitaxel assay. A water-soluble tetrazolium (WST)-8 test and the Cell Counting Kit-8 (Dojindo Laboratories) were used to evaluate paclitaxel sensitivity. At 48 h after transfection, HuCCT1 cells were seeded (10 000 cells/well) into 96-well
plates in 100 µL medium containing 10% FBS prior to drug exposure. After 24 h pre-incubation the cells were treated with various concentrations of paclitaxel for 48 h. Then, 10 µL WST-8 reagent was added and the cells were incubated for an additional 2 h at 37°C. Viability was determined using colorimetry by absorbance at 450 nm (xMark Microplate Absorbance Spectrophotometer).

**Statistical analysis.** Data for the continuous variables are expressed as the mean ± SEM. Significance was determined using Student’s t-tests and ANOVA. Statistical analysis of the immunohistochemical staining data was performed using the chi-squared test. Survival curves were calculated using the Kaplan–Meier method and analyzed with the log-rank test. Prognostic factors were examined by univariate and multivariate analyses using a Cox proportional hazards model. All differences were deemed significant at \( P < 0.05 \) and all statistical analyses were performed with JMP software, version 5.01 (SAS Institute Inc., Cary, NC, USA).

**Results**

**Immunohistochemical staining of STMN1 and p27 in EHCC tissues.** STMN1 expression was evaluated using immunohistochemistry in 80 EHCC samples. Thirty-three samples (41.2%) were negative for STMN1 expression (Fig. 1a) and 47 samples (58.8%) were positive for cytoplasmic STMN1 expression (Fig. 1b). Nuclear p27 expression was also evaluated in these samples. Twenty-five (31.2%) samples were positive for p27 expression (Fig. 1c) and 55 samples (68.8%) were negative (Fig. 1d). High STMN1 expression was associated with low p27 nuclear expression (\( P = 0.0011 \); Table 1). Cytoplasmic p27 expression was evaluated in the same EHCC samples; 43 (54.4%) samples demonstrated high cytoplasmic staining for p27 expression (Fig. 1d), whereas 36 (45.6%) samples exhibited low p27 expression (Fig. 1c). High STMN1 expression was associated with high p27 cytoplasmic expression (\( P = 0.0063 \); Table 1).

**STMN1 expression correlates with venous invasion and Ki-67 labeling index in EHCC tissues.** The correlations between STMN1 expression and clinicopathological findings are shown in Table 1. We considered the following factors: patient age, patient gender, tumor stage, lymph node metastasis, lymphatic invasion, venous invasion, nerve invasion, infiltrating type and TNM stage (UICC 7th). The results showed a correlation between high STMN1 expression and venous invasion (\( P = 0.0021 \)). We also examined the association between STMN1 expression and the Ki-67 labeling index to evaluate proliferation. High-STMN1-expressing patients had a significantly higher Ki-67 labeling index in comparison to low-STMN1-expressing patients (\( P = 0.0001 \)).

**Prognostic significance of STMN1 expression in EHCC.** The prognostic significance of STMN1 expression on postoperative recurrence-free survival (RFS) and cancer-specific survival (CSS) is shown in Figure 2. The STMN1-positive group had significantly poorer prognoses than the STMN1-negative group, regarding both RFS (\( P = 0.0222 \)) and CSS (\( P = 0.0061 \)). For CSS, STMN1 expression was prognostic for poor survival in the univariate analysis (Table 2; \( P = 0.0044 \)). Multivariate analysis also showed STMN1 expression is prognostic for poor survival (Table 2; \( P = 0.0165 \)). Interestingly, other existing clinicopathological factors were not significantly and independently associated with shorter CSS, whereas STMN1 expression in EHCC remained more significant than the presence of lymph node metastasis (Table 2; hazard ratio [HR], 1.696; 95% confidence interval [CI], 1.10–2.76).

**STMN1 and p27 cross interact in cultured EHCC cells.** To examine the protein complexes of STMN1 and p27 in HuCCT1 cells, we performed PLA, which revealed the complexes as red spots in the cytoplasm (Fig. 3a). Thus, STMN1 interacts with p27 in the cytoplasm, but not in the nucleus, of EHCC cells.

**siRNA-mediated STMN1 suppression and p27 expression in HuCCT-1 cells.** Two siRNA complexes were used to knock down STMN1 expression in HuCCT-1 cells. Suppression of STMN1 by siRNA1 and siRNA2 was demonstrated using western blotting 96 h after transfection (Fig. 3b). Next, we examined the effect of STMN1 knockdown on p27 expression. STMN1 depletion induced total p27 protein expression and

![Fig. 1. Immunohistochemical staining of stathmin1 (STMN1) and p27 in primary extrahepatic cholangiocarcinoma (EHCC) samples. (a) Low STMN1 expression in a primary EHCC specimen (original magnification, \( \times 400 \)). (b) High STMN1 expression in a primary EHCC specimen (original magnification, \( \times 400 \)). (c) High nuclear p27 expression and low cytoplasmic p27 expression in a primary EHCC specimen (original magnification, \( \times 400 \)). (d) Low nuclear p27 expression and high cytoplasmic p27 expression in a primary EHCC specimen (original magnification, \( \times 400 \)). Figures a, c and b, d show images from the same cases.](image-url)
Suppression of STMN1 reduces proliferation and sensitizes EHCC cells to paclitaxel. We assessed the relationship between EHCC proliferation and STMN1 expression. WST assays revealed that the proliferation of STMN1-knockdown cells was significantly lower than in the parent and negative-control cells ($P = 0.0011$; Table 1). In addition, p27 expression was also evaluated on each EHCC samples. Forty-three out of 80 samples (54.4%) demonstrated high cytoplasmic staining for p27 expression (Fig. 1d), whereas 55 (68.8%) samples were low for p27 expression (Fig. 1c). Moreover, the samples exhibiting high STMN1 expression were associated with low p27 nuclear expression ($P = 0.0001$; Table 1). In addition, p27 expression was also associated with high STMN1 expression ($P = 0.0063$; Table 1).

**STMN1 expression correlates with venous invasion and Ki-67 labeling index in EHCC tissues.** The correlations between STMN1 expression and clinicopathological findings are displayed in Table 1. Regarding the clinicopathological findings, we considered the following factors: patient age, patient gender, tumor stage, lymph node metastasis, lymphatic invasion, venous invasion, nerve invasion, infiltrating type and TNM stage (UICC 7th). The results revealed that STMN1-high expression was correlated with venous invasion ($P = 0.0001$).

In addition, we examined the association between STMN1 expression and the Ki-67 labeling index to evaluate proliferation ability. The STMN1-high-expression patients had a significantly higher Ki-67 labeling index than the low-expression patients ($P < 0.0001$).

**Prognostic significance of STMN1 expression in EHCC.** The prognostic significance of STMN1 expression on postoperative RFS and CSS rates are displayed in Figure 2. The STMN1-positive group had significantly poorer prognoses than the STMN1-negative group, regarding both RFS ($P = 0.0222$) and CSS ($P = 0.0061$). For CSS, STMN1 expression was a prognostic factor for poor survival in the univariate analysis (Table 2; $P = 0.0044$). In the multivariate analysis, STMN1 expression was also a prognostic factor for poor survival (Table 2; $P = 0.0165$). Interestingly, other existing clinicopathological factors were not significantly and independently associated with shorter CSS, whereas the detection of STMN1 expression in EHCC remained prognostically more significant than the presence of lymph node metastasis with regard to CSS (Table 2; HR, 1.696; 95% CI, 1.10–2.76).

**STMN1 and p27 cross-interactinn EHCC cells in vitro.** To examine the protein complexes formed between STMN1 and p27 in HuCCT1 cells, we performed PLA. As a result, the formations of STMN1 and p27 complexes were detected in the cytoplasm as red spots (Fig. 3a). This result demonstrates that STMN1 interacts with p27 in the cytoplasm, but not in the nucleus, of EHCC cells.

**Effect of siRNA-mediated STMN1 suppression on p27 expression in HuCCT-1 cells.** Two siRNA complexes were used to knockdown STMN1 expression in the HuCCT-1 cells. The suppression of STMN1 by siRNA1 and siRNA2 was demonstrated using western blotting 96 h after transfection (Fig. 3b). Next, we examined the effect of STMN1 knockdown on p27 expression. The depletion of STMN1 increased p27 expression on total protein and also had a tendency to increase nuclear p27 expression (Fig. 3b).

**Suppression of STMN1 reduces proliferation and sensitizes EHCC cells to paclitaxel.** We assessed the relationship between the proliferative ability of EHCC cells and STMN1 expression. The cellular proliferation ability was evaluated using the WST assay, which revealed that the proliferation of STMN1-knockdown cells significantly diminished compared with the

---

**Table 1. Clinicopathological characteristics of extrahepatic cholangiocarcinoma patients according to stathmin expression**

| Factor                      | STMN1 low expression (n = 33) | STMN1 high expression (n = 47) | P-value |
|-----------------------------|-------------------------------|--------------------------------|--------|
| Age (years)                 |                               |                                |        |
| ≤65                         | 13                            | 18                             | 0.9211 |
| >65                         | 20                            | 29                             |        |
| Sex                         |                               |                                |        |
| Male                        | 23                            | 35                             | 0.6389 |
| Female                      | 10                            | 12                             |        |
| Differentiation             |                               |                                |        |
| Well                        | 9                             | 9                              | 0.2563 |
| Moderate                    | 15                            | 26                             |        |
| Poor                        | 8                             | 14                             |        |
| Tumor stage                 |                               |                                |        |
| T1–2                        | 20                            | 19                             | 0.0745 |
| T3–4                        | 13                            | 28                             |        |
| Lymph node metastasis       |                               |                                |        |
| –                           | 19                            | 27                             | 0.9908 |
| +                           | 14                            | 20                             |        |
| Lymphatic invasion          |                               |                                |        |
| –                           | 7                             | 4                              | 0.1070 |
| +                           | 26                            | 43                             |        |
| Venous invasion             |                               |                                |        |
| –                           | 12                            | 4                              | 0.002* |
| +                           | 21                            | 43                             |        |
| Distant metastasis          |                               |                                |        |
| –                           | 32                            | 45                             | 0.7740 |
| +                           | 1                             | 2                              |        |
| Infiltration                |                               |                                |        |
| α                           | 0                             | 2                              | 0.1179 |
| β                           | 17                            | 31                             |        |
| γ                           | 15                            | 14                             |        |
| TNM stage (UICC)            |                               |                                |        |
| 0, I                        | 11                            | 11                             | 0.3297 |
| II, III, IV                 | 22                            | 36                             |        |
| Nuclear p27                 |                               |                                |        |
| High expression             | 17                            | 8                              | 0.001* |
| Low expression              | 16                            | 39                             |        |
| Cytoplasmic p27             |                               |                                |        |
| High expression             | 12                            | 31                             | 0.006* |
| Low expression              | 21                            | 15                             |        |
| Ki-67 labeling index (mean ± SD) | 9.28 ± 13.5 62.1 ± 31.9 | <0.0001* |

*P < 0.05. STMN1, stathmin1; TNM, tumor-node-metastasis; UICC, Union for International Cancer Control.

---

*staining for STMN1 expression (Fig. 1b). Nuclear p27 expression was also evaluated in the 80 EHCC samples. Twenty-five (31.2%) samples demonstrated positive nuclear staining for p27 expression (Fig. 1c), whereas 55 (68.8%) samples were negative for p27 expression (Fig. 1d). Moreover, the samples exhibiting high STMN1 expression were associated with low p27 nuclear expression ($P = 0.0011$; Table 1). In addition, p27 expression was also associated with high STMN1 expression ($P = 0.0063$; Table 1).
parent and negative-control cells (P < 0.01; Fig. 3c). Moreover, STMN1-knockdown cells exhibited significantly higher sensitivity to paclitaxel than the control cells (P < 0.01; Fig. 3d).

**Discussion**

In the present study, we demonstrated that high STMN1 expression is associated with poor prognosis in primary EHCC samples. Moreover, high STMN1 expression is related to low nuclear p27 expression and high cytoplasmic p27 expression. In the *in vitro* STMN1 knockdown analysis, proliferative ability was reduced and paclitaxel sensitivity was increased in transfected cells compared with the control cells. In addition, STMN1 knockdown increased p27 expression.

In the immunohistochemical analysis, high STMN1 expression correlated to poor RFS and CSS prognosis. Moreover, based on the multivariate analysis of CSS, high STMN1 expression translated into an independent prognostic factor. Some reports have also revealed that high STMN1 expression is related to poor prognosis in the following cancers: oral squamous cell carcinoma; diffuse type gastric cancer; colon cancer; hepatocellular cancer; and urothelial carcinoma. The results of the present study are in agreement with these previous reports. Therefore, STMN1 is expected to serve as a prognostic-predictive marker of EHCC.

In the present study, high STMN1 expression was associated with venous invasion in EHCC. Jeon et al. reported this association in diffuse type gastric carcinoma and showed that in *in vitro* STMN1 suppression inhibited migration and invasion in gastric cancer cells. Baldassare et al. reported that STMN1 promotes invasion in sarcoma and regulates microtubule stability following adhesion to the extracellular matrix. STMN1 also regulated invasion in hepatocellular carcinoma. Our results were consistent with these previous reports and indicate that STMN1 is associated with invasion in EHCC.

Previous studies have examined the relationship between STMN1 and p27. Baldassare et al. reported that STMN1 bound to p27 in the cytoplasm of sarcoma cells and that high-STMN1-expressing and low-p27-expressing cells demonstrate increased proliferation and invasion ability. However, the authors did not describe in detail whether cytoplasmic p27 regulates STMN1 function or whether cytoplasmic STMN1 inhibits the import of p27 into the nucleus. In our immunohistochemical analysis of EHCC, high-STMN1-expressing samples exhibited a significant tendency for low nuclear p27 expression and high cytoplasmic p27 expression. Using a PLA assay, STMN1 was

**Table 2. Univariate and multivariate analysis of prognostic factors using the Cox proportional hazards model**

| Factor                     | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | RR  | 95% CI     | P-value | RR  | 95% CI     | P-value |
| Age (<65//>66)             | 0.994 | 0.70–1.38 | 0.9720 | –   | –           | –       |
| Sex (M/F)                  | 0.753 | 0.49–1.09 | 0.1392 | –   | –           | –       |
| Tumor stage (T1–2/3–4)     | 2.314 | 1.18–4.71 | 0.0131* | 2.031 | 0.97–4.39 | 0.0577 |
| Lymph node metastasis (–/+)| 1.742 | 1.23–2.50 | 0.0013* | 1.48  | 1.02–2.20 | 0.0379* |
| Lymphatic invasion (–/+    | 1.631 | 0.97–3.33 | 0.0649 | –   | –           | –       |
| Venous invasion (–/+       | 1.619 | 1.02–2.97 | 0.0410* | 1.039 | 0.59–1.99 | 0.898  |
| Distant metastasis (–/+    | 1.803 | 0.29–5.99 | 0.4582 | –   | –           | –       |
| Adjuvant therapy (–/+      | 0.467 | 0.25–0.90 | 0.0242* | 0.346 | 0.17–0.70 | 0.0035* |
| Nuclear p27 expression (–/+| 0.596 | 0.36–0.89 | 0.0011* | 0.811 | 0.47–1.30 | 0.401  |
| STMN1 expression (–/+      | 1.688 | 1.16–2.58 | 0.0044* | 1.696 | 1.10–2.76 | 0.0165* |

*P < 0.05. CI, confidence interval; RR, relative risk; STMN1, stathmin1.
shown to interact with p27 directly in the cytoplasm of HuCCT1 cells in vitro. Moreover, siRNA-mediated STMN1 knockdown triggered increased p27 expression and the proliferative ability of STMN1-suppressed cells significantly diminished. Interestingly, p27-degradation promotion has been reported in the cytoplasm but not in the nucleus during the G0–G1 transition. From these results it is suggested that STMN1 interacts with p27 in the cytoplasm, inhibits the function of nuclear p27 via the degradation of cytoplasmic p27 and leads to the progression of cancer. S phase kinase-associated protein 2 (SKP2) promotes p27 degradation via the ubiquitin–proteasome system and p27 upregulation facilitated by a SKP2 inhibitor significantly suppresses the cell cycle and results in lower proliferation potency. Therefore, p27 regulation by STMN1 targeting might provide a promising therapeutic tool for several cancers including EHCC.

Some studies have examined the relationship between STMN1 expression and taxane anticancer drugs. STMN1 overexpression levels are associated with paclitaxel sensitivity in ovarian cancer and breast cancer cells. Iancu et al. reported that taxol and anti-STMN1 therapy produced a synergetic anticancer effect on a leukemic cell line. Moreover, Alli et al. also reported that STMN1 overexpression increases the rate of cell death, decreases microtubule polymerization, which markedly decreases taxane binding, and prevents cells from entering mitosis. In the present study, STMN1 knockdown increased paclitaxel sensitivity, which is consistent with previous reports. Although few anti-microtubule cancer drugs have produced a positive effect on EHCC in current clinical practice, the combination of taxane and anti-STMN1 drugs may provide a prospective therapy against various cancers in the future.

In conclusion, STMN1 expression contributed to a shorter duration of RFS and reduced CSS in patients with EHCC. Therefore, the evaluation of STMN1 expression in EHCC might be a useful predictor of recurrence and poor prognosis. Moreover, high STMN1 expression was associated with low p27 expression in clinical EHCC samples and STMN1 suppression regulated proliferation and paclitaxel sensitivity in an EHCC cell line. Our results suggest that STMN1 in EHCC may be a promising molecular target for controlling cancer progression and taxane resistance via p27 regulation.

Acknowledgments
The authors thank Ms Yukie Saito, Ms Tomoko Yano, Ms Tomoko Ubukata, Ms Yuka Matsui, Ms Ayaka Ishida and Ayaka Ishikubo for their excellent assistance.

Disclosure Statement
The authors have no conflicts of interest.

References
1 Vasilieva LE, Papadimitriou SI, Dourakis SP. Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012; 11: 349–59.
2 Skipworth JR, Olde Damink SW, Imber C, Bridgewater J, Pereira SP, Malago M. Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Aliment Pharmacol Ther 2011; 34: 1063–78.
3 Pichlmayr R, Weimann A, Klempnauer J et al. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg 1996; 224: 628–38.
4 Klempnauer J, Ridder GJ, Werner M, Weimann A, Pichlmayr R. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer 1997; 79: 26–34.
5 Alli E, Yang JM, Hacht WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007; 26: 1003–12.
Supporting Information

Additional supporting information may be found in the online version of this article:

Fig. S1. Immunohistochemical staining of stathmin1 (STMN1) in primary esophageal cancer served as a positive control.

Fig. S2. Immunohistochemical staining of nuclear p27 in primary esophageal cancer served as a positive control.

Fig. S3. Immunohistochemical staining of cytoplasmic p27 in primary esophageal cancer served as a positive control.

Table S1. Criteria of Immunohistochemistry evaluation.